News|Articles|December 4, 2025
De-Risking Clinical Development: Strategic Multipliers in Global Trials
Author(s)Seriant
Trending on PharmExec
1
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
2
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
3
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
4
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
5